Close Menu

CRUK

Researchers from the TRACERx consortium analyzed blood and tumor samples to tease out features of lung cancers that are more likely to recur.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.

Concordance numbers and early evidence of clinical impact from a 100-patient first phase were sufficient to expand to another 450 individuals.

Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

A brief recap of Genetics/Genomics news the week of Dec 14, 2018: AstraZeneca, NeoGenomics, Fluidigm, Luminex, Petco Foundation, and SQI Diagnostics

Research continues to show that it is possible to detect genetic signs of cancer in a blood sample without the need to measure specific oncogenic mutations.

Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.

The American Association for Cancer Research annual meeting wrapped up today in Chicago. Below are selected business briefs from the conference.

The company is collaborating with two UK institutes to assess whether its Signatera ctDNA technology can detect disease recurrence in women treated for breast cancer.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.